Trial Profile
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes (BOOST: JAPAN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/insulin aspart (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BOOST; BOOST-JAPAN
- Sponsors Novo Nordisk
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 07 Nov 2011 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 07 Nov 2011 Results reported in a Novo Nordisk media release.